Clinical Trial Database, LIVE on the MOASC website

This Weekly’s Hot Topics

  • Clinical Trial Database, LIVE on the MOASC website MOASC News
  • MOASC’s Lung Cancer Webinar Series, to begin in January 2022 MOASC Programs
  • Cancer Research Through a Health Equity Lens California News

MOASC has been able to create a Clinical Trial Database, LIVE on the MOASC website at www.moasc.org, through such generous grants and affording new opportunities for MOASC members. The MOASC Clinical Trial Committee is actively looking for ways to assist its members with Clinical Trial promotion and recruitment, through the creation of a database for both physicians and patients. To read more click here and go to MOASC News.

We are proud to announce our inaugural Lung Cancer Webinar Series, which is slated to begin in January of 2022.  The goal of this webinar series is to engage our members in lively discussion and review the latest updates in the management of lung cancer.  We will hold each discussion once a month virtually and set aside one hour to review a particular topic within this ever more differentiated area of oncology. To read more click here and go to MOASC News/MOASC Programs.

Last Thursday, 11/18, the American Cancer Society Cancer Action Network presented a virtual event Cancer Research Through a Health Equity Lens. The content of the program exceeded expectations and the questions from all attendees raised the quality of the discussions, which will help shape ACS CAN advocacy efforts to address health equity in cancer research so that all individuals have a fair and just opportunity to prevent, find, treat, and survive cancer. MOASC was among 13 other sponsors of this program to further ASC CAN mission!. To read more click here and go to California News.

CMS gave drugmakers six more months to comply with the Trump-era regulation requiring them to calculate the “best price” for drugs under Medicaid’s drug rebate program using discounts they offer patients. The new final rule will officially delay best prices reporting from Jan. 1, 2022, to July 1, 2022. To read more click here and go to Medicare News/CMS News.

Health insurers, employers and other group health plan sponsors must report prescription drug and health coverage costs for consumers under a federal regulation published last week. The interim finale rule is the fourth regulation to date implementing the No Surprises Act. The Health and Human Services Department, Labor Department, Treasury Department and Office of Personnel Management promulgated the regulation. To read more click here and go to National News.

To read the complete California Oncology Newsletter edition, click on the date below.

November 23, 2021



No comments have been posted yet.